Navigation Links
In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop
Date:10/7/2008

udies in models for several complement-mediated diseases showed that targeted inhibition of the alternative complement pathway slowed or halted disease progression in these models. Sekine et al. investigated whether TT30 prevented progression of renal disease in a lupus nephritis murine model (Poster #174). TT30 is a fusion protein coupling domains from complement receptor 2 (CR2) with the alternative pathway inhibitor factor H (fH). Treatment with the CR2 domain alone led to decreases in autoantibodies, while treatment with TT30 resulted in additional beneficial effects including significantly reduced renal injury, proteinuria and anti-dsDNA antibody levels compared to controls. Therefore, the dual action of TT30 (CR2 and fH) prevented disease progression in this animal model.

Thurman et al. (Poster #171) compared the effect of systemic administration of TT30 to the effect of CR2-Crry in an airway hyper-responsiveness asthma animal model. CR2-Crry is an inhibitor of the alternative, classical and lectin complement pathways whereas TT30 inhibits only the alternative pathway. The study showed that both TT30 and CR2-Crry significantly reduced airway hyper-responsiveness. This suggests that targeting the alternative complement pathway, while keeping the classical and lectin complement pathways unaffected, may be sufficient to control complement-mediated diseases and thus reduce the risk of infection.

Wet AMD animal model study suggests an alternative to intraocular drug administration

Currently marketed therapies for wet AMD require intraocular injections. In a wet AMD animal model, Rohrer et al. (Poster #202) tested whether TT30 could be effective in preventing progression of choroidal neovascularization following argon laser photocoagulation if TT30 was injected intraocularly or intravenously. The Rohrer team demonstrated that TT30 prevented progression of choroidal neovascularization regardless of the mode of administration. Besides adding furth
'/>"/>

SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
2. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
3. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
4. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
5. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
6. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
7. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
10. Tobira Therapeutics Inc. Receives US Patent for TBR-652
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Research and Markets( http://www.researchandmarkets.com/research/58tdl6/pharmaceutical ... Grade Sodium Chloride Market by Applications, by Region - ... their offering. The pharmaceutical grade sodium chloride ... between 2014 and 2019 in terms of volume, and ... 2019. The report on Pharmaceutical grade sodium ...
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... 6, 2015 Akcea Therapeutics, a wholly-owned ... ), announced today that the U.S. Food and ... volanesorsen (ISIS-APOCIII Rx ) for the treatment of ... a rare genetic disease characterized by extremely high ... Phase 2 study published in the NEJM in ...
Breaking Medicine Technology:Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6
... Oct. 7 Cornerstone Pharmaceuticals, Inc., a privately-held pharmaceutical ... A. Weinberg, Ph.D., a founding member of the Whitehead ... at MIT, has joined the company,s Scientific Advisory Board. ... first human oncogene (the ras oncogene that ...
... MAARSSEN, The Netherlands, Oct. 7 CPhI Worldwide ... largest annual meeting - returns to Madrid on 12 - 15 ... contract services and P-MEC equipment and technology events ... banner by the new, biotech-focused BioPh . The new ...
Cached Medicine Technology:Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board 2Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board 3CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence 2CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence 3
(Date:7/7/2015)... ... July 07, 2015 , ... Nationally-renowned attorneys in the realm ... the Invokana Ketoacidosis Lawsuit Center . The website provides information on Invokana ... persons wishing to learn more about Invokana lawsuits for kidney problems, ketoacidosis, heart ...
(Date:7/7/2015)... Chicago, Illinois (PRWEB) , ... July 07, 2015 ... ... in government program modernization, today announced they have been selected by the Department ... Validation (IV&V) services for its Medicaid Management Information System (MMIS) and Integrated Contact ...
(Date:7/6/2015)... ... July 06, 2015 , ... Respected southern California personal injury ... 2015, marking him as an attorney who has sharp legal skills as well as ... Distinction Award for 2015 from Martindale-Hubbell and a Top 10 Award from The National ...
(Date:7/6/2015)... , ... July 06, 2015 , ... On June 22, 2015, Fox News in a report titled “ Female Hair ... they turn age 35 a quarter of all women in the U.S. will suffer from ... is stigmatized and rarely discussed. One woman, a former beauty queen, who was interviewed for ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... The Asian-Pacific ... in 2014. It is expected to grow at a CAGR of over 3.2 percent ... , The growth is likely to be mainly spurred by an anticipated launch of ...
Breaking Medicine News(10 mins):Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 3Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2
... in order to show- how eating patterns can stop you getting ... 60 or over living in many countries . They have ... lots of green leafy vegetables, beans, olive oil, nuts and multigrain ... and sugar was also linked to keeping a smoother skin.// ...
... brain power, according to Japanese research. ,It is thought ... or restrict the hardening of the arteries which could ... ,However, there are other factors linked to moderate ... IQ. The researchers, at the National Institute for Longevity ...
... of mouthwash is being hailed as a new weapon against ... some deodorants, seems to be able to prevent the growth ... of mosquitoes which causes as many as 3.2m deaths worldwide ... the agent has yet to be fully developed, the increasing ...
... India has finally decided to get its act together on ... get a large number of laboratories activated on testing them, ... plants to ensure the raw material itself meets standards. The ... a series of measures to boost the medicinal plants sector. ...
... is an effective treatment for neuropathic pain (nerve pain).,Neuropathic ... tricyclic antidepressants(TCAs) But these drugs have side effects ... sensations associated with nerve pain. ,Now researchers ... SR (sustained release) is effective against nerve pain in ...
... lupus erythematosus (SLE)--usually referred to simply as lupus--is the ... by inflammation and damage to tissue and organs throughout ... central nervous system. Lupus is an autoimmune disorder, meaning ... ,New research into lupus suggests how the immune ...
Cached Medicine News:
... cleanser will not leave your hands dry, ... With persistent Antimicrobial action, CHG Skin Cleanser ... gram-negative and gram-positive bacteria, fungi, and yeasts. ... second hand wash. The solution does not ...
IV Prep Antiseptic Wipes are effective and easy to apply. They are ideal for preparation of the skin prior to a ventipuncture or injection....
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
... Triad Plus Skin Protectant Swabsticks prepare ... dressing or bandage. When dry, they leave ... This provides a clean surface and a ... affect the adhesion of a dressing or ...
Medicine Products: